Gynecologic Cancer

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Susan K. Bohnenkamp, an oncology clinical nurse specialist, is recognized for her compassionate and expert care, going above and beyond to support her patients through their cancer journey.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

Patients with cervical cancer demonstrated better sexual health and quality of life after undergoing simple hysterectomies versus radical hysterectomies.

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.

When I was diagnosed with stage 1A cervical cancer, I realized that life is short and I want to spend my time being the best version of myself.

From pro wrestling legend Sid Vicious dying of cancer to Nicole Eggert’s breast cancer update, here’s what’s happening in the oncology space this week.

Even when I didn’t feel like riding, brushing and grooming her kept my spirits up and provided a social outlet that wasn’t medically oriented.

Even though my wife became quadriplegic after her breast cancer progressed, our insurance still did not help us out, so I became her caregiver full-time.

The Food and Drug Administration approved Jemperli with carboplatin and paclitaxel for primary advanced or recurrent endometrial cancer.

Patients with advanced gynecologic cancer given IMNN-001 with presurgical chemotherapy tended to live nearly a year longer.

A novel antibody-drug conjugate received an investigational new drug application for patients with gynecologic and lung cancers.

Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed.

Here are eight poems about my experience as a caregiver to my wife during her final days.

While I was receiving treatment for endometrial cancer, I received so much support from friends, coworkers and people from my church.

After leaving an unsupportive support group for ovarian cancer, I finally found my pillars of support.